Article Per Year (5 Year)
p-Index From 2021 - 2026
0.562
P-Index
This Author published in this journals
All Journal Malang Respiratory Journal Jurnal Klinik dan Riset Kesehatan
Santosa, Andrew
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Education Health Professions Immunology & microbiology Medicine & Pharmacology Nursing Public Health Other

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

 1 
Analisis Ketahanan Hidup Pasien Kanker Paru di RSUD Dr. Saiful Anwar Pratiwi, Suryanti Dwi; Setyawan, Ungky Agus; Falyani, Silvy Amalia; Permatasari, Adinda Pramitra; Santosa, Andrew; Febriawati, Juwita; Prasetyo, Kevin Wahyudy; Yokanan
Jurnal Klinik dan Riset Kesehatan Vol 3 No 3 (2024): Edisi Juni
Publisher : RSUD Dr. Saiful Anwar Province of East Java

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.11594/jk-risk.03.3.2

Abstract

Pendahuluan: Kanker paru insidennya sebesar 14% dari semua kanker, dan merupakan penyebab utama kematian akibat keganasan di seluruh dunia. Berbagai studi menunjukkan perbedaan terkait angka ketahanan hidup, serta berbagai faktor yang signifikan terkait dengan angka ketahanan hidup tersebut pada pasien kanker paru. Tujuan: Penelitian ini bertujuan untuk mengetahui profil dan angka tahan hidup (ATH) pasien kanker paru yang mendapatkan kemoterapi di RSUD dr. Saiful Anwar pada tahun 2018-2020. Metode: Studi kohort retrospektif dengan menggunakan data rekam medik pasien terdiagnosis kanker paru pada tahun 2018 – 2020 yang mendapatkan kemoterapi. Analisis data dilakukan menggunakan uji log rank Mantel Cox, serta ketahanan hidup pasien berupa progression free survival (PFS) dan overall survival (OS) ditampilkan dengan kurva Kaplan Meier. Hasil: Pasien kanker paru terbanyak berjenis kelamin laki-laki (73,2%). Adenokarsinoma merupakan jenis sel kanker paru terbanyak (59,8%) dengan mutasi EGFR wild type 20,6%. Karboplatin–Paklitaksel merupakan jenis kemoterapi yang paling sering digunakan (54,6%). Analisis ATH menunjukkan terdapat hubungan signifikan antara usia dengan PFS dan OS (p < 0,05). Kesimpulan: Berbagai faktor seperti jenis kelamin, jenis sel kanker, mutasi EGFR, dan jenis kemoterapi diketahui tidak berkaitan signifikan dengan ATH pasien kanker paru. Hubungan signifikan antara usia dengan ATH menunjukkan potensi faktor usia sebagai prediktor ketahanan hidup pasien kanker paru.
Analisis Ketahanan Hidup Pasien Kanker Paru di RSUD Dr. Saiful Anwar Pratiwi, Suryanti Dwi; Setyawan, Ungky Agus; Falyani, Silvy Amalia; Permatasari, Adinda Pramitra; Santosa, Andrew; Febriawati, Juwita; Prasetyo, Kevin Wahyudy; Yokanan
Jurnal Klinik dan Riset Kesehatan Vol 3 No 3 (2024): Edisi Juni
Publisher : RSUD Dr. Saiful Anwar Province of East Java

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.11594/jk-risk.03.3.2

Abstract

Background: Comprising 14% of all cancer, lung cancer is the main cause of cancer-related mortality worldwide. Previous studies showed various findings regarding the survival rate of lung cancer, and factors significantly correlated with survival rate in lung cancer patients. Aim: This research aims to identify the profile and survival rate of lung cancer patients receiving chemotherapy in Saiful Anwar General Hospital from 2018 to 2020. Methods: This cohort retrospective study used medical records of patients diagnosed with lung cancer who underwent chemotherapy from 2018 to 2020. Data analysis was done using the Mantel Cox log rank test. Survival data shown as progression free survival (PFS) and overall survival (OS) were shown using Kaplan-Meier curves. Results: Subjects were largely male (73,2%). Adenocarcinoma is the most often type of lung cancer found (59,8%) with wild type EGFR mutation being the most prevalent (20,6%). Carboplatin – Paclitaxel is the most widely used chemotherapy regimen (54,6%). Survival analysis showed a significant correlation between age, OS, and PFS (p < 0,05) Conclusion: Various factors such as gender, cancer cell type, EGFR mutation, and chemotherapy regimen were not found to be related to survival rate in lung cancer patients. A significant correlation between age and survival rate showed potential in utilizing age as a predictor of survival rate in lung cancer patients.
Management of Pneumomediastinum Patients in COVID-19: Rare Cases Santosa, Andrew; Djajalaksana, Susanthy; Listyoko, Aditya; Erawati, Dini
Malang Respiratory Journal Vol. 6 No. 2 (2024): September 2024
Publisher : Universitaas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.mrj.2024.006.02.04

Abstract

Background: Spontaneous pneumomediastinum in patients with confirmed cases of Covid-19 is a very rare clinical finding in the world, especially in Indonesia. This is considered an indication of concern for a more serious medical problem. Aim: This case report discusses the management of COVID-19 patients with pneumomediastinum. Case: A 30 year old man came to the hospital with the main complaint of shortness of breath and cough. The patient was diagnosed with a confirmed case of Covid-19 and received therapy using High Flow Nasal Cannula (HFNC) as a therapeutic modality. After 5 days in the hospital, the patient's shortness of breath felt increasingly severe, and he began to feel chest pain and swelling around the chest area which spread to both sides of his neck. A thorax x-ray examination showed pneumomediastinum and subcutaneous emphysema, then a chest CT scan was performed and the results showed pneumomediastinum which was thought to be caused by esophageal rupture. After we communicated with the Thoracic Surgery Department, conservative therapy was recommended. Conclusion: Covid-19 infection can cause hypoxaemic respiratory failure and acute respiratory distress syndrome, both of which can be deadly. Supplementation of high-flow nasal cannula (HFNC) oxygen therapy can be very beneficial for patients, but can cause dangerous side effects such as pneumomediastinum. Pneumomediastinum (PM) is the presence of open air in the mediastinal cavity. In this case, we suspect that the pneumomediastinum was the result of Covid-19-related alveolar damage and esophageal rupture, and not due to the use of HFNC. Pneumomediastinum complications need to be detected early, so that management can reduce associated morbidity and mortality. Keywords: Pneumomediastinum; COVID-19, HFNC
Co-Authors Djajalaksana, Susanthy Erawati, Dini Falyani, Silvy Amalia Febriawati, Juwita Kevin Wahyudy Prasetyo Listyoko, Aditya Permatasari, Adinda Pramitra Pratiwi, Suryanti Dwi Setyawan, Ungky Agus Yokanan